Conversion of the receivership proceedings into judicial liquidation proceedings
DEINOVE - Update on the receivership proceedings
DEINOVE - Update on the Receivership Proceedings
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that its Board of Directors has approved the consolidated financial statements for the first half of 2022.
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that a poster titled « DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection » is to be presented at the ESCMID/ASM conference taking place in Dublin, from October 4 to 7.
DEINOVE- Second convening to a Combined General Meeting on May 30, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial...
DEINOVE presents its financial results and the advancement of its programs for 2021 Favorable opinion of the DSMB and continuation of the Phase II of of DNV3837 in the treatment of Clostridioides...
Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial...
Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance The AGIR program, supported by the Investments for the Future Program,...
DEINOVE (Euronext Growth Paris : ALDEI), a French biotech company pioneering the exploration and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces its collaboration with the Max Mousseron Institute of Biomolecules (IBMM) and the Physical Measurement Laboratory (LMP) of the University of Montpellier for the co-development of new analytical approaches based on the use of Ultra High Resolution Mass Spectrometry, over a 30-month period. This project benefits from a €990K funding from the European Regional Development Fund (FEDER) and the Occitania Region.